<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">HEPATITIS B VACCINE (RECOMBINANT) <img border="0" src="../images/pr.gif"/></span><br/>(hep'a-ti-tis)<br/><span class="topboxtradename">Engerix-B, </span><span class="topboxtradename">Recombivax HB<br/></span><b>Classifications:</b> <span class="classification">antiinfective</span>; <span class="classification">vaccine</span><br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>10 mcg/mL, 5 mcg/0.5 mL, 40 mcg/mL (Recombivax); 20 mcg/mL, 10 mcg/0.5 mL (Engerix-B)</p>
<h1><a name="action">Actions</a></h1>
<p>Suspension of inactivated and purified hepatitis B surface antigen (HBsAg) derived from human plasma of screened asymptomatic
         HBsAg-positive carriers of hepatitis B virus. Hepatitis B vaccine recombinant is the first vaccine produced by gene splicing.
         No human plasma is used in its production.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>The recommended 3-dose regimen produces active immunity against hepatitis B infection by inducing protective antibody (anti-HBs)
         formation.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>To promote active immunity in individuals at high risk of potential exposure to hepatitis B virus or HBsAg-positive materials.
         Has been used simultaneously (into different sites) with hepatitis B immune globulin (H-BIG) for post-exposure prophylaxis
         in selected patients and in infants born to HBsAg-positive mothers.
      </p>
<h1><a name="contrain">Contraindications</a></h1>
<p>History of allergic reaction to hepatitis B vaccine or to any ingredient in the formulation; HBsAg carriers. Safe use during
         pregnancy (category C) and lactation is not established.
      </p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Compromised cardiopulmonary status, serious active infection or fever; thrombocytopenia or other bleeding disorders.</p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Hepatitis B Prophylaxis</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IM</span> Recombivax 1 mL (10 mcg) at 0, 1, and 6 mo; Engerix-B 1 mL (20 mcg) at 0, 1, and 6 mo or 0, 1, 2, and 12 mo<br/><span class="rdage">Child:</span> <span class="rdroute">IM</span> Recombivax 0.5 mL (5 mcg) at 0, 1, and 6 mo; Engerix-B 0.5 mL (10 mcg) at 0, 1, and 6 mo or 0, 1, 2, and 12 mo<br/><br/><span class="indicationtitle">Dialysis and Immunodeficient Patients</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IM</span> Recombivax 2 mL (20 mcg) at 0, 1, and 6 mo Engerix-B 2 mL (40 mcg) at 0, 1, and 6 mo or 0, 1, 2, and 12 mo<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Intramuscular</span><br/><ul>
<li>Give preferably into the deltoid and in neonates into the anterolateral thigh, avoiding blood vessels and nerves. Carefully
            aspirate to prevent inadvertent intravascular injection.
         </li>
<li>Have epinephrine immediately available to treat anaphylaxis.</li>
<li>Shake vial well before withdrawing dose to assure uniform suspension.</li>
<li>Store unopened and opened vials at 2°8° C (36°46° F) unless otherwise directed. Avoid freezing
            (freezing destroys potency).
         </li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">Body as a Whole:</span> <span class="speceff-common">Mild local tenderness at injection site, local inflammatory reaction</span> (swelling, heat, redness, induration, pain); <span class="speceff-common">fever, malaise, fatigue,</span> headache, dizziness, faintness, leg cramps, myalgia, arthralgia. <span class="typehead">GI:</span> Nausea, vomiting, diarrhea. <span class="typehead">Skin:</span> Rash, urticaria, pruritus. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> No clinically significant interactions established. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Slowly absorbed from IM site. <span class="typehead">Onset:</span> 2 wk. <span class="typehead">Peak:</span> 6 mo. <span class="typehead">Duration:</span> At least 3 y. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li> 							Note: The ACIP recommends serologic confirmation of postvaccination immunity in patients undergoing dialysis and in immunodeficient
            patients. 						
         </li>
<li>Monitor temperature. Some patients develop a temperature elevation of 38.3° C (101° F) following vaccination that
            may last 1 or 2 d.
         </li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Learn potential adverse reaction.</li>
<li>Do not breast feed while taking this drug without consulting physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>